Business Wire

Ascom Myco smarttelefon for helsesektoren har fullført Mobilelrons tester for Android-kompatibilitet.

Del

Ascom Myco, en av verdens første smarttelefoner som er spesialbygd for helsesektoren, har fullført Android selvtestprogrammet til MobileIron. Det betyr at Ascom Myco støtter Googles standard API-er (Application Program Interfaces) som brukes av den ledende leverandøren innen mobilsikkerhet, MobileIron (NASDAQ: MOBL).

«Disse testene understreker hvor hensiktsmessig Ascom Myco er i helsesektoren», sier Henrik Sandberg, Alliances Manager hos Ascom Wireless Solutions. «Blant annet viser det at IT-ansvarlige og administratorer kan styre en gruppe Ascom Myco smarttelefoner sentralt på et bestemt sykehus eller annen virksomhet.» Hvis for eksempel en Ascom Myco-telefon som er styrt av MobileIron skulle forsvinne, kan administratoren fjernstyre at alle data i telefonen slettes.

Andre viktige funksjoner som aktiveres av API-ene inkluderer låsing av telefoner, GPS-posisjonering, ekstern installasjon av en Root Certification Authority og fjernstyrt implementering av sikkerhetspolicyer.

«Disse og andre funksjoner gir IKT-administratorer i helsesektoren de fjernstyrte, sentraliserte verktøyene de trenger for å beskytte pasientinformasjon», sier Sandberg. Ascom Myco er utviklet for å dele pasientinformasjon og sørge for at informasjonen er sikret.

«Ascom Mycos fullførte test illustrerer en økende bruk av mobile enheter i flere bransjer», sier Jeff Ratzlaff, Vice President, Business Development, MobileIron. «Det som er spesielt spennende med Ascom Myco, er det spesifikke fokuset på helsesektoren. Ascom Myco kjører ikke bare på det åpne Android-systemet som kan støtte en rekke programmer for helsesektoren, men den er også kompatibel med API-ene vi bruker for å levere virksomhetssikkerhet.

Om Ascom Wireless Solutions

Ascom Wireless Solutions ble grunnlagt i 1955 som en divisjon av Ascom AG, og leverer virksomhetskritiske IKT-løsningen til den globale helsesektoren. I dag er mer enn 100 000 systemer installert på sykehus, i eldreomsorgen og andre områder hvor virksomhetskritisk kommunikasjonen er avgjørende. Fremfor alt vil vi gjøre en forskjell innen helsesektoren.

Om MobileIron

MobileIron danner et sikkerhetsmessig grunnlag for virksomheter rundt om i verden som ønsker å gå over til en mer Mobile First virksomhet. For mer informasjon, besøk www.mobileiron.com

Ansvarsfraskrivelse

Kompatibilitetutsagnet ovenfor baseres på informasjon rapportert av produsenter av Android-telefoner som har utført testene med MobileIrons produkter eller tjenester. MobileIron kan ikke garantere at enhetene vil være kompatible med MobileIrons produkter eller tjenester. Kundene bør også være klar over at selv om en enhet er kompatibel med en versjon av MobileIrons produkter eller tjenester, er enheten ikke nødvendigvis kompatibel med tidligere eller fremtidig versjoner av samme MobileIron-produktet eller tjeneste.

Contact information

Ascom
Henrik Sandberg
Alliances Manager, Ascom, Sverige
Telefon: +46 31 55 94 03
E-post: henrik.sandberg@ascom.com
eller
MobileIron
Clarissa Horowitz
Telefon: +1 415 608 6825
E-post: clarissa@mobileiron.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

ADC Therapeutics Presents Interim Phase I Data from its Novel Antibody-Drug Conjugate ADCT-40211.12.2017 06:00Pressemelding

ADC Therapeutics (ADCT), an oncology drug discovery and development company that specializes in the development of proprietary Antibody Drug Conjugates (ADCs) targeting major cancers, today announced clinical data from two ongoing Phase I clinical trials evaluating ADCT-402 (loncastuximab tesirine or “Lonca-T”) in important subtypes of lymphoma and leukemia. The data were presented at the 59th American Society of Hematology (ASH) Annual Meeting in Atlanta, USA. 1. Interim results of a Phase I open label, single agent, dose-escalating study of ADCT-402 evaluating tolerability, safety, pharmacokinetics and efficacy in patients with relapsed or refractory B-cell Non-Hodgkin Lymphoma Dr. Brad Kahl, M.D., Professor for Medical Oncology at the Washington University School of Medicine in St. Louis, said: “A significant number

GA Telesis Launches Leveraged Finance Group with the Appointments of David Lloyd and Nolan Heske11.12.2017 05:01Pressemelding

GA Telesis, LLC (“GAT”) announces the launch of its Leveraged Finance Group (“LFG”) to provide secured aircraft financing for lessors, investors, and airlines. GAT has appointed David Lloyd and Nolan Heske as Managing Directors of LFG to pursue the development, execution and growth of this strategy. The LFG management team has over 35 years of combined experience in the aircraft and transportation finance sector. Prior to joining GAT, Mr. Lloyd and Mr. Heske cofounded Air Funding in 2016 to provide an alternative source of direct lending on commercial aircraft to lessors and airlines. Prior to Air Funding, David Lloyd spent 12 years at Carlson Capital as Head of Credit, Airlines & Aerospace. Mr. Lloyd was the group founder and was responsible for a portfolio with peak assets of $475 million. Mr. Lloyd also held executive positions at Credit Suisse and Chase Securities. No

AstraZeneca’s Calquence (acalabrutinib) Shows Potential in Chronic Lymphocytic Leukaemia Trials10.12.2017 22:45Pressemelding

AstraZeneca and Acerta Pharma, its haematology research and development centre of excellence, today presented results from the Phase Ib/II ACE-CL-003 clinical trial (Abstract #432) and updated results from the Phase I/II ACE-CL-001 (Abstract #498) clinical trial that are testing Calquence (acalabrutinib) alone and in combination for the treatment of chronic lymphocytic leukaemia (CLL) in multiple treatment settings. The findings were presented during two oral sessions at the 59th American Society of Hematology (ASH) Annual Meeting & Exhibition in Atlanta, USA. Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca, said: “These data add to the growing body of evidence that supports the potential of Calquence in the treatment of chronic lymphocytic leukaemia, a life-threatening disease that affects tens of thousands of people aroun

Celgene Corporation and bluebird bio Announce Updated Results from Ongoing Multicenter Phase 1 Study of bb2121 Anti-BCMA CAR T Cell Therapy in Patients with Late Stage Relapsed/Refractory Multiple Myeloma at ASH Annual Meeting10.12.2017 15:30Pressemelding

Celgene Corporation (NASDAQ: CELG) and bluebird bio, Inc. (Nasdaq: BLUE) today announced that updated results from the ongoing CRB-401 Phase 1 clinical study of bb2121, an investigational anti-B-cell maturation antigen (BCMA) CAR T cell therapy, in 21 patients with late-stage relapsed/refractory multiple myeloma will be presented in an oral presentation at the American Society of Hematology (ASH) Annual Meeting in Atlanta, Georgia. The objective of this Phase 1 dose-escalation study is to evaluate safety and efficacy of bb2121 and determine a recommended Phase 2 dose. “Celgene has a longstanding commitment to patients with multiple myeloma through our extensive research efforts in this deadly blood cancer,” said Nadim Ahmed, President, Hematology and Oncology for Celgene. “Looking ahead, we see BCMA as an important target in this disease and we believe bb2121 has the potenti

Kite Announces Long-Term Data From Pivotal ZUMA-1 Study of Yescarta™ (Axicabtagene Ciloleucel) in Patients With Refractory Large B-cell Lymphoma10.12.2017 15:30Pressemelding

Kite, a Gilead Company (Nasdaq: GILD), announced long-term follow-up data from the pivotal ZUMA-1 study of Yescarta™ (axicabtagene ciloleucel) in patients with refractory large B-cell lymphoma. With a minimum follow-up of one year after a single infusion of Yescarta (median follow-up of 15.4 months), 42 percent of patients continued to respond to therapy, including 40 percent with a complete remission. Detailed results from this updated analysis were simultaneously presented at the Annual Meeting of the American Society of Hematology (ASH) in Atlanta and published in The New England Journal of Medicine. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171210005072/en/ Yescarta is the first chimeric antigen receptor T (CAR T) cell therapy to be approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult

Takeda and Seattle Genetics to Present Positive Data from Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS® (brentuximab vedotin) in Frontline Advanced Hodgkin Lymphoma10.12.2017 13:00Pressemelding

Takeda Pharmaceutical Company Limited (TSE:4502) and Seattle Genetics, Inc. (NASDAQ: SGEN) today announced that data from the Phase 3 ECHELON-1 clinical trial evaluating ADCETRIS (brentuximab vedotin) as part of a frontline combination chemotherapy regimen in untreated advanced classical Hodgkin lymphoma will be presented in the Plenary Scientific Session at the 59th American Society of Hematology (ASH) annual meeting on Sunday, December 10, 2017. The data were also simultaneously published online in the New England Journal of Medicine and will be published in the print edition on January 25, 2017. Topline data were reported in June 2017 demonstrating the ECHELON-1 trial met its primary endpoint of a statistically significant improvement in modified progression-free survival (modified PFS) per Independent Review Facility (IRF) versus the control arm. ADCETRIS is an antibody-drug con

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom